GenMark Diagnostics

GenMark Diagnostics is a molecular diagnostics company focused on developing and commercializing its sensor detection technology. The Company’s electrochemical technology enables the detection of up to 72 distinct biomarkers in a single sample. Its XT-8 System has received 510(k) clearance from the United States Food and Drug Administration (FDA) and is designed to support a range of molecular diagnostic tests with a compact workstation and self-contained, disposable test cartridges. Within 30 minutes of receipt of an amplified deoxyribonucleic acid (DNA) sample, its XT-8 System produces results. The XT-8 System supports up to 24 test cartridges, which can be run independently, and are targeted for hospitals and reference laboratories. The Company is also developing its next-generation platform, the AD-8 System, to integrate DNA amplification with its sensor detection technology to enable technicians to place a minimally prepared patient sample into its test cartridge.

GenMark Diagnostics (GNMK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will GenMark Diagnostics (GNMK) Report Negative Earnings Next Week? What You Should Know

Will GenMark Diagnostics (GNMK) Report Negative Q2 Earnings? What You Should Know

GenMark is slowly putting some execution concerns to rest, and the full FDA approval of the company's three-part BCID panel is a big help.

Better Execution Leading To Better Valuation For GenMark

GenMark Diagnostics, Inc. (GNMK) CEO Hany Massarany on Q1 2019 Results - Earnings Call Transcript

GenMark Diagnostics (GNMK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

News for GenMark Diagnostics Stock (GNMK)